AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33472757 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 97
Study 33472757 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hand massage)
Number of subjects: 97
Study 32605501 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% 5‐fluorouracil cream
Number of subjects: 72
Study 32605501 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% 5‐fluorouracil cream
Number of subjects: 72
Study 32605501 — intervention group
Group type: COMPARATOR
Intervention: 90% trichloroacetic acid
Number of subjects: 72
Study 34217258 — intervention group
Group type: EXPERIMENTAL
Intervention: Information leaflet on the benefits and harms of mammography screening
Number of subjects: 11119
Study 34217258 — intervention group
Group type: COMPARATOR
Intervention: Usual invitation letter
Number of subjects: 11119
Study 35802150 — intervention group
Group type: EXPERIMENTAL
Intervention: RIRS without UAS (Group 1)
Number of subjects: 60
Study 35802150 — intervention group
Group type: COMPARATOR
Intervention: 11Fr/13Fr Boston scientific Navigator™ UAS (Group 2)
Number of subjects: 60
Study 35802150 — intervention group
Group type: COMPARATOR
Intervention: 11Fr/13Fr dual lumen ClearPetra™ UAS (Group 3)
Number of subjects: 60
Study 34582454 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in caregivers' gender-equitable attitudes
Number of subjects: 732
Study 34582454 — intervention group
Group type: EXPERIMENTAL
Intervention: Older girls
Number of subjects: 732
Study 34996820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac, 10 mg, three times daily for a maximum of 5 days
Number of subjects: 56
Study 34996820 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (Control group)
Number of subjects: 56
Study 34878869 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash plus intervention
Number of subjects: 904
Study 35416167 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D model‐assisted surgery
Number of subjects: 32
Study 35416167 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 32
Study 33781284 — intervention group
Group type: EXPERIMENTAL
Intervention: Theory‐informed in‐practice training session plus individualised audit and feedback
Number of subjects: 228
Study 33781284 — intervention group
Group type: COMPARATOR
Intervention: Audit and feedback alone
Number of subjects: 228
Study 33510184 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated triglycerides and pro-inflammatory markers (TNF? and IL6)
Number of subjects: 215
Study 33510184 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of triglycerides, TNF?, and IL6 coupled with low levels of HDL-C
Number of subjects: 215
Study 33510184 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly controlled diabetes (HbA1c > 6.5)
Number of subjects: 215
Study 33510184 — intervention group
Group type: COMPARATOR
Intervention: Diabetes
Number of subjects: 215
Study 35786347 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Laser Sintering (SLS)
Number of subjects: 18
Study 35786347 — intervention group
Group type: COMPARATOR
Intervention: Conventional Lost-Wax Casting
Number of subjects: 18
Study 34103623 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel exercise with three different moments of inertia
Number of subjects: 21
Study 34103623 — intervention group
Group type: EXPERIMENTAL
Intervention: Flywheel exercise (general)
Number of subjects: 21
Study 36318322 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-congruent (UC) device
Number of subjects: 185
Study 36318322 — intervention group
Group type: COMPARATOR
Intervention: Condylar-stabilizing (CS) device
Number of subjects: 185
Study 36318322 — intervention group
Group type: COMPARATOR
Intervention: Posterior-stabilized (PS) device
Number of subjects: 185
Study 33555114 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial Flow Regulator (AFR) device
Number of subjects: 53
Study 32178430 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility training (supervised, group-based, twice a week for one year)
Number of subjects: 85
Study 32178430 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group
Number of subjects: 85
Study 32737893 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1000 mg intravenous)
Number of subjects: 76
Study 32737893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 35820112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage II-III patients.
Number of subjects: 57
Study 35820112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multimodality therapy including four cycles of chemotherapy followed by involved field radiation therapy (45 Gy) for stage IVa patients.
Number of subjects: 57
Study 35820112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multimodality therapy including four cycles of chemotherapy and one cycle of high-dose carboplatin, thiotepa, and etoposide with autologous hematopoietic stem-cell support for stage IVb patients.
Number of subjects: 57
Study 33369684 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality-based neck-specific sensorimotor training
Number of subjects: 51
Study 33369684 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation programme)
Number of subjects: 51
Study 33369684 — intervention group
Group type: COMPARATOR
Intervention: General sensorimotor training (group therapy)
Number of subjects: 51
Study 34542910 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered anonymous questionnaire assessing misconceptions about oral radiology and medicine
Number of subjects: 1380
Study 32827410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic breathing exercises (DBE) for 5 minutes every day
Number of subjects: 60
Study 32827410 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DBE)
Number of subjects: 60
Study 34119566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal Clonidine Group (ITCG)
Number of subjects: 60
Study 34119566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Clonidine Group (IVCG)
Number of subjects: 60
Study 34119566 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 60
Study 33015926 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support team (NST) intervention
Number of subjects: 61
Study 33015926 — intervention group
Group type: COMPARATOR
Intervention: No nutritional support team (NST) intervention (Control)
Number of subjects: 61
Study 34165612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) group practiced guided mindfulness meditation for a minimum of 10 minutes each day for 10 days.
Number of subjects: 0
Study 34165612 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WC) group
Number of subjects: 0
Study 34165612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) group
Number of subjects: 0
Study 34732775 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 60
Study 34732775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 34244182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful gratitude journaling
Number of subjects: 92
Study 34244182 — intervention group
Group type: COMPARATOR
Intervention: Routine journaling (Control)
Number of subjects: 92
Study 36385638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention for seniors (MBIS)
Number of subjects: 24
Study 36385638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for anxiety
Number of subjects: 24
Study 36385638 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual control group
Number of subjects: 24
Study 32641330 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative recorded music interventions in addition to standard care
Number of subjects: 170
Study 32641330 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 170
Study 33535786 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted years of education
Number of subjects: 0
Study 33535786 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted smoking
Number of subjects: 0
Study 33535786 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 0
Study 33535786 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-hip ratio
Number of subjects: 0
Study 33535786 — intervention group
Group type: EXPERIMENTAL
Intervention: Education, body mass index, and smoking
Number of subjects: 0
Study 34708513 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental diet (Ex-diet)
Number of subjects: 115
Study 34708513 — intervention group
Group type: COMPARATOR
Intervention: Control diet (C-diet)
Number of subjects: 115
Study 32269052 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab
Number of subjects: 28
Study 32269052 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab + Tremelimumab
Number of subjects: 28
Study 32269052 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 28
Study 35120572 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 33
Study 35120572 — intervention group
Group type: COMPARATOR
Intervention: Double-blind placebo (DBP)
Number of subjects: 33
Study 33058795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol (2 g every 8 hours for 7–14 days)
Number of subjects: 152
Study 33058795 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy (pre-specified by the investigator, maximum of three drugs for 7–14 days)
Number of subjects: 152
Study 33058795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Number of subjects: 152
Study 33058795 — intervention group
Group type: COMPARATOR
Intervention: Best available therapy
Number of subjects: 152
Study 32701597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (SSRI)
Number of subjects: 0
Study 32701597 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 32701597 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 32701597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35493817 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (2 mA, 20 min, 15 sessions over 3 weeks)
Number of subjects: 24
Study 35493817 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 35493817 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 24
Study 32221151 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine and ketorolac (PE/K) 1.0%/0.3%
Number of subjects: 72
Study 32221151 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine (PE) 1.0%
Number of subjects: 72
Study 33527476 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-kindness exercises
Number of subjects: 122
Study 33527476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness exercises
Number of subjects: 122
Study 33527476 — intervention group
Group type: EXPERIMENTAL
Intervention: Common humanity exercises
Number of subjects: 122
Study 33527476 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122
Study 36060713 — intervention group
Group type: EXPERIMENTAL
Intervention: Online mindfulness program (group M)
Number of subjects: 90
Study 36060713 — intervention group
Group type: COMPARATOR
Intervention: Placebo sessions (group C)
Number of subjects: 90
Study 32075010 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-LC (structured supervised exercise program + low-carbohydrate meals)
Number of subjects: 64
Study 32075010 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic state (βHB ≥0.3 mmol/L)
Number of subjects: 64
Study 32075010 — intervention group
Group type: COMPARATOR
Intervention: EX-CO (structured supervised exercise program + standard dietary advice)
Number of subjects: 64
Study 36120766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization with movement (MWM)
Number of subjects: 45
Study 36120766 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle energy technique (MET)
Number of subjects: 45
Study 36120766 — intervention group
Group type: COMPARATOR
Intervention: Control group (home exercise program)
Number of subjects: 45
Study 32940893 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Tanshinone IIA Sulfonate (STS), n = 192
Number of subjects: 372
Study 32940893 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control), n = 180
Number of subjects: 372
Study 33327227 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulated food (n = 80)
Number of subjects: 120
Study 33327227 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n = 40)
Number of subjects: 120
Study 34802052 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-brow technique
Number of subjects: 47
Study 34802052 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid crease technique
Number of subjects: 47
Study 34802052 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mini-incision technique
Number of subjects: 47
Study 34802052 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 47
Study 34824982 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive-behavioral therapy (ICBT) including psychoeducation, cognitive restructuring, attentional training, and exposure.
Number of subjects: 464
Study 34824982 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesized change mechanisms include the increase of knowledge about SAD, the decrease of dysfunctional cognitions, the decrease of self‐focused attention, and the decrease of avoidance and safety behaviors.
Number of subjects: 464
Study 36409435 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-931 80 mg tablet
Number of subjects: 20
Study 36409435 — intervention group
Group type: COMPARATOR
Intervention: TAK-931 80 mg PIC
Number of subjects: 20
Study 36409435 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-931 50 mg PIC QD
Number of subjects: 20
Study 32633151 — intervention group
Group type: EXPERIMENTAL
Intervention: Humor correction
Number of subjects: 0
Study 32633151 — intervention group
Group type: COMPARATOR
Intervention: Non-humor correction
Number of subjects: 0
Study 32091032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with pollen extracts, 3 intralymphatic inguinal injections before the first pollen season.
Number of subjects: 18
Study 32091032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralymphatic immunotherapy (ILIT) with pollen extracts.
Number of subjects: 18
Study 32091032 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group).
Number of subjects: 18
Study 35598154 — intervention group
Group type: EXPERIMENTAL
Intervention: Splanchnic ablation for volume management (SAVM)
Number of subjects: 18
Study 33734539 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video-based intervention
Number of subjects: 172
Study 33734539 — intervention group
Group type: EXPERIMENTAL
Intervention: Written vignette intervention
Number of subjects: 172
Study 33734539 — intervention group
Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 172
Study 35807924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low avocado allotment (3 avocados)
Number of subjects: 0
Study 35807924 — intervention group
Group type: EXPERIMENTAL
Intervention: High avocado allotment (14 avocados)
Number of subjects: 0
Study 34296837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity low-amplitude (HVLA) thrust manipulation
Number of subjects: 10
Study 34296837 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 10
Study 32966320 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous training session
Number of subjects: 341
Study 32966320 — intervention group
Group type: EXPERIMENTAL
Intervention: Current training session
Number of subjects: 341
Study 32966320 — intervention group
Group type: COMPARATOR
Intervention: Participants with less than 1,000 flight hours
Number of subjects: 341
Study 32966320 — intervention group
Group type: COMPARATOR
Intervention: Participants with more than 1,000 flight hours
Number of subjects: 341
Study 34694872 — intervention group
Group type: EXPERIMENTAL
Intervention: Telacebec (Q203) 10 to 800 mg
Number of subjects: 56
Study 34694872 — intervention group
Group type: EXPERIMENTAL
Intervention: Telacebec (Q203) 10 to 800 mg (fed condition)
Number of subjects: 56
Study 34694872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 32721815 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 100
Study 32721815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 100
Study 35401774 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT) + physiotherapy treatment (PT)
Number of subjects: 76
Study 35401774 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy treatment (PT)
Number of subjects: 76
Study 34284834 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood exposed group
Number of subjects: 9055
Study 34284834 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescence exposed group
Number of subjects: 9055
Study 34284834 — intervention group
Group type: COMPARATOR
Intervention: Fetal/infant exposed group
Number of subjects: 9055
Study 34284834 — intervention group
Group type: COMPARATOR
Intervention: Unexposed group
Number of subjects: 9055
Study 34284834 — intervention group
Group type: COMPARATOR
Intervention: Males in all famine exposed groups
Number of subjects: 9055
Study 32213042 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy for 3 days or less
Number of subjects: 296
Study 32213042 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial therapy for 4 days or more
Number of subjects: 296
Study 36067369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol)
Number of subjects: 11486
Study 36067369 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) in men with baseline 25‐hydroxyvitamin D <20 ng/mL
Number of subjects: 11486
Study 36067369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11486
Study 34741513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chatbot recruitment
Number of subjects: 935
Study 34741513 — intervention group
Group type: COMPARATOR
Intervention: Telephone-based recruitment
Number of subjects: 935
Study 34966900 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (125 mg subcutaneous every week)
Number of subjects: 88
Study 34966900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 34966900 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (during open-label extension)
Number of subjects: 88
Study 34966900 — intervention group
Group type: COMPARATOR
Intervention: Placebo (transitioned to abatacept during open-label extension)
Number of subjects: 88
Study 35789818 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fascia iliaca compartment block (CFICB)
Number of subjects: 60
Study 35789818 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled intravenous analgesia (PCIA)
Number of subjects: 60
Study 35792520 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 0
Study 35792520 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone
Number of subjects: 0
Study 35792520 — intervention group
Group type: COMPARATOR
Intervention: Inotrope therapy
Number of subjects: 0
Study 35792520 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan
Number of subjects: 0
Study 33452192 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 138
Study 33452192 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel (chemotherapy)
Number of subjects: 138
Study 33452192 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and cediranib
Number of subjects: 138
Study 34237265 — intervention group
Group type: COMPARATOR
Intervention: Normal blood pressure (sBP <120 mm Hg and dBP <80 mm Hg)
Number of subjects: 21069
Study 34237265 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe stage 2 hypertension (sBP ≥160 mm Hg or dBP ≥110 mm Hg)
Number of subjects: 21069
Study 34237265 — intervention group
Group type: COMPARATOR
Intervention: Elevated blood pressure (sBP 120–129 mm Hg and dBP <80 mm Hg)
Number of subjects: 21069
Study 34237265 — intervention group
Group type: COMPARATOR
Intervention: Stage 1 hypertension (sBP 130–139 mm Hg or dBP 80–89 mm Hg, or both)
Number of subjects: 21069
Study 34237265 — intervention group
Group type: COMPARATOR
Intervention: Non‐severe stage 2 hypertension (sBP 140–159 mm Hg or dBP 90–109 mm Hg, or both)
Number of subjects: 21069
Study 32398341 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days antibiotic treatment
Number of subjects: 3626
Study 32398341 — intervention group
Group type: COMPARATOR
Intervention: 14 days antibiotic treatment
Number of subjects: 3626
Study 35264365 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial epicardial conduction time (LAECT) measured in patients with conduction block across the roof and trigone lesion.
Number of subjects: 121
Study 35264365 — intervention group
Group type: EXPERIMENTAL
Intervention: LAECT
Number of subjects: 121
Study 35264365 — intervention group
Group type: EXPERIMENTAL
Intervention: LAECT, previously failed catheter ablation, and BMI
Number of subjects: 121
Study 32910135 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab (dosing every four months)
Number of subjects: 0
Study 32910135 — intervention group
Group type: EXPERIMENTAL
Intervention: Faricimab (dosing quarterly)
Number of subjects: 0
Study 32910135 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study 36493791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks
Number of subjects: 852
Study 36493791 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 2 weeks
Number of subjects: 852
Study 36493791 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab 40 mg every 2 weeks
Number of subjects: 852
Study 36493791 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 160 mg every 4 weeks (after switch from placebo at week 16)
Number of subjects: 852
Study 36493791 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment-emergent adverse events
Number of subjects: 852